SamaCare named 2026 Prix Galien USA finalist for Best Digital Health Solution. Aug 13, 2026, 07:05 ET Recognition honors SamaCare's AI-powered Medical Benefit Prior Authorization Intelligence Platform for helping patients access specialty therapies faster SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ - SamaCare, the AI-powered medical benefit prior authorization intelligence platform, today announced it has been named a 2026 Prix Galien USA finalist in the Best Digital Health Solution category for its AI-powered Medical Benefit Prior Authorization Intelligence Platform. Widely regarded as one of the most prestigious honors in life sciences innovation, the Prix Galien recognizes breakthroughs with the potential to improve human health. SamaCare was selected among 23 Best Digital Health Solution nominees in a year marking the 20th anniversary of the Prix Galien USA Awards. For patients prescribed specialty therapies for cancer, autoimmune disease, neurologic disease, retinal disease, and other serious or progressive conditions, the next step after diagnosis should be treatment. Instead, many face a complex administrative journey before therapy can begin, including benefits verification, prior authorization, payer review, step therapy, appeals, follow-up, scheduling, and rescheduling. These delays can mean disease progression, relapse, anxiety, treatment non-starts, and worsening outcomes. SamaCare was founded to address that gap between prescription and treatment start. The company's platform transforms fragmented medical benefit prior authorization into intelligent healthcare infrastructure, helping providers navigate payer requirements, reduce administrative burden, and move patients to therapy faster. "Every breakthrough therapy solves one scientific challenge: how to treat disease," said Syam Palakurthy, Founder and CEO of SamaCare. "But there is another challenge that determines whether innovation reaches patients: whether people can actually access the therapies their physicians prescribe. Being named a Prix Galien USA finalist is deeply meaningful because this award recognizes health impact. Our team is focused on making sure patients do not get stuck in administrative limbo after their doctor has already decided what treatment they need." Medical benefit prior authorization remains one of healthcare's most fragmented access challenges. Unlike retail pharmacy workflows, medical benefit therapies are often administered in specialty practices, infusion centers, or physician offices, with payer requirements that vary by plan, therapy, site of care, diagnosis, documentation, and route of administration. For patients with serious or progressive disease, delays can carry clinical consequences. For providers, the process consumes staff time that could otherwise support patient care. SamaCare's platform unifies prior authorization creation, submission, tracking, and management across payers and plans. By combining workflow automation, payer policy intelligence, AI-driven guidance, and real-world provider data, SamaCare helps specialty practices anticipate requirements, avoid preventable delays and denials, and maintain visibility into authorizations in flight. The platform also converts millions of prior authorization interactions into real-world patient access intelligence. This gives life sciences market access, patient services, and provider engagement teams a clearer view into the administrative barriers patients and providers encounter after a therapy is prescribed. These insights can help identify access friction earlier, inform targeted provider support, and improve the script-to-therapy journey. "SamaCare's innovation is not AI for AI's sake," Palakurthy added. "It is AI applied to one of the least visible but most consequential parts of healthcare: the operational path between a prescription and a patient actually receiving treatment. Our goal is to make that path faster, clearer, and less painful for the providers and patients navigating it every day." SamaCare supports provider-administered specialty medications across oncology, ophthalmology/retina, neurology, rheumatology, immunology, gastroenterology, rare disease, ambulatory infusion, and other specialty care settings. Its intelligent system for medical benefit prior authorization has helped reduce delays, denials, and therapy abandonment while creating a new source of real-world access intelligence for the healthcare ecosystem. About SamaCare SamaCare is an AI-powered insights and interventions platform designed to accelerate patient access to specialty therapies by unifying and optimizing the prior authorization process for provider-administered medications. The platform aggregates and analyzes real-world data from millions of prior authorizations across a nationwide network of providers, delivering actionable insights and in-workflow support that reduce delays, denials, and therapy abandonment. SamaCare partners with pharmaceutical manufacturers, providers, and patient access teams to improve the script-to-therapy journey and help patients start and stay on treatment. For more information, visit www.samacare.com. About The Galien Foundation The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve human health. Established in Paris in 1970 in honor of Galen, the father of medical science and modern pharmacology, the Prix Galien is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research. Today, the Prix Galien operates through 16 chapters spanning more than 75 countries across Africa, the Americas, Asia, and Europe. For more information, visit www.galienfoundation.org. SOURCE SamaCare

SamaCare ranks in top 25% of 2026 Inc. 5000 for third consecutive year. Aug 11, 2026, 07:02 ET AI-powered prior authorization company named No. 1021, reflecting continued growth of its platform for specialty practices and market access teams SAN FRANCISCO, Aug. 11, 2026 /PRNewswire/ - SamaCare, the AI-powered medical benefit prior authorization platform, today announced it has been ranked No. 1021 on the 2026 Inc. 5000 list, placing the company in the top 25% of America's fastest-growing private companies for the third consecutive year. SamaCare's continued recognition reflects growing demand for technology that helps specialty practices, pharmaceutical manufacturers, and patient access teams reduce administrative barriers between prescription and treatment start. Over the past year, SamaCare has expanded its AI prior authorization platform, introduced an insights solution for life sciences market access teams, and published the industry's first Market Access Benchmarks for medical benefit prior authorization performance. "Being named to the Inc. 5000 list for the third year running is a meaningful milestone for our team, but the real story is the problem we are helping the industry solve," said Syam Palakurthy, Founder and CEO of SamaCare. "Specialty practices are navigating increasingly complex payer requirements, while life sciences teams need clearer visibility into the access barriers that affect whether patients can start and stay on therapy. Our growth reflects the urgency of that need, and our continued focus on using AI, workflow automation, and real-world access data to help patients receive the treatments their physicians prescribe." SamaCare's platform unifies prior authorization workflows for provider-administered specialty medications across payers and plans. By combining automation, payer policy intelligence, workflow data, and AI-driven insights, SamaCare helps practices reduce administrative burden while giving life sciences teams a clearer view into patient access barriers that are difficult to see through claims or traditional hub data alone. In 2026, SamaCare launched its Market Access Benchmarks, the first public benchmarks focused on medical benefit prior authorization performance. The benchmarks provide quarterly visibility into net approval rates and time to resolution across medical benefit drugs, helping market access, patient services, and provider engagement teams better understand where access friction occurs and where targeted interventions may improve patient starts. SamaCare has also continued to expand its insights solution for market access teams, enabling life sciences organizations to identify payer, provider, specialty, and workflow-level barriers that can affect therapy uptake. These insights help teams move beyond lagging indicators and better understand the real-world administrative pathways patients and providers must navigate after a therapy is prescribed. "Every company on the Inc. 5000 has a story of perseverance, smart decision making, and a refusal to sit still," said Mike Hofman, editor-in-chief of Inc. "Their growth reflects more than strong financial performance; it reflects creativity, resilience, and the customer focus required to build companies that make a lasting impact. We congratulate all honorees on this significant achievement." For the full Inc. 5000 list, honoree company profiles, and a searchable database by industry and location, visit www.inc.com/inc5000. About SamaCare SamaCare is an AI-powered insights and interventions platform designed to accelerate patient access to specialty therapies by unifying and optimizing the prior authorization process for provider-administered medications. The platform aggregates and analyzes real-world data from millions of prior authorizations across a nationwide network of providers, delivering actionable insights and in-workflow support that reduce delays, denials, and therapy abandonment. SamaCare partners with pharmaceutical manufacturers, providers, and patient access teams to improve the script-to-therapy journey and help patients start and stay on treatment. For more information, visit www.samacare.com. SOURCE SamaCare